Aquestive Therapeutics Inc. (AQST)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Here's Why Aquestive Therapeutics (AQST) Is a Great 'Buy the Bottom' Stock Now
Aquestive Therapeutics (AQST) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Aquestive Therapeutics: Anaphylm Will Probably Survive This Regulatory Hurdle
Aquestive Therapeutics faces increased regulatory and timeline risk after the FDA identified deficiencies in Anaphylm's NDA, causing a 40% stock price decline. The FDA's communication is so far procedural, not substantive or a definitive rejection; issues are more likely related to manufacturing or packaging rather than efficacy or safety. AQST's $120 million, at a current burn rate of $5 million a month, shall provide sufficient runway for the company to address this setback.
Down 37% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround
Aquestive Therapeutics (AQST) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Aquestive Therapeutics: Looking For The PDUFA Run-Up
Aquestive Therapeutics is positioned for a potential PDUFA run-up ahead of Anaphylm's FDA decision on January 31, 2026. Anaphylm's needle-free, oral epinephrine alternative could capture 8-12% of the $2.7B U.S. auto-injector market by 2033. AQST's technical setup, undervaluation, and strong double-digit growth estimates support a bullish outlook, but volatility and binary regulatory risk remain high.
Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why
Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aquestive Therapeutics, Inc. (AQST) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development Transcript
Aquestive Therapeutics, Inc. ( AQST ) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development November 6, 2025 12:00 PM EST Company Participants Daniel Barber - CEO, President & Director Melina Cioffi - Senior Vice President of Regulatory Affairs Cassie Jung - Chief Operating Officer Gary Slatko - Interim Chief Medical Officer Sherry Korczynski - Chief Commercial Officer Ernie Toth - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler & Co., Research Division Presentation David Amsellem Piper Sandler & Co., Research Division All right. Well, good afternoon, everyone.
Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call Transcript
Aquestive Therapeutics, Inc. ( AQST ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Daniel Barber - CEO, President & Director Ernie Toth - Chief Financial Officer Sherry Korczynski - Chief Commercial Officer Gary Slatko - Interim Chief Medical Officer Conference Call Participants Brian Korb David Amsellem - Piper Sandler & Co., Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division François Brisebois - LifeSci Capital, LLC, Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Denis Reznik - Raymond James & Associates, Inc., Research Division James Molloy - Alliance Global Partners, Research Division Presentation Operator Good day, and thank you for standing by.
Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
Aquestive Therapeutics: A Measured Bet
Aquestive Therapeutics leverages its PharmFilm® platform to develop Anaphylm, a sublingual epinephrine film targeting a $1B+ U.S. market. AQST's management, including former EpiPen marketing leadership, and a recent $85M equity raise position the company for a strong commercial launch. Base case projections see Anaphylm capturing 15–25% market share, supporting an $8–$20 per-share valuation if launch and adoption succeed.
Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?
Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst
Aquestive Therapeutics's Anaphylm could be the first FDA-approved, non-invasive, orally delivered epinephrine for anaphylaxis, with a PDUFA date set for January 2026. FDA's decision not to convene an advisory committee is a positive signal, and clinical data seems to strongly support Anaphylm's safety and efficacy. If approved, Anaphylm could capture significant market share, potentially driving Aquestive's valuation above $1bn and offering >50% upside for investors.
